Investor Information

Market Opportunities

Topical Drug Delivery

Set forth below is the overall annual dermatology market potential broken down by indication. Those portions of the overall market that are labeled in a blue font are the portions of the overall market that Quinnova's products utilizing the TwinDerm, TanDerm and Dermal Delivery Foam are targeting and will continue to target.



Prospective Investors

Please enter your username and password in the log-in area at the top of this page to gain access to Quinnova's Secure Data Room. If you do not have a username and password and would like to request one, please submit your first and last name and your e-mail address in the form below, or send an e-mail to Quinnova's Investing team at: investing@quinnova.com.
Back to top

Request Access to Quinnova's Data Room

Use the form below to ensure that your message is handled with care and directed to the proper individual.





 

At Quinnova, we are committed to protecting your privacy. Any information submitted to Quinnova will be used to communicate to you regarding Quinnova and investing with Quinnova.
Back to top





News Room

Quinnova Pharmaceuticals, Inc. announced the commercial launch of Hydro 40™ Foam. Containing 40 percent urea in a water-lipid based foam.

Click here to download our June 13, 2007 press release.

If you would like to be alerted to Quinnova News as it becomes available, please sign-up using the form below.